BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close to $200 million through an initial public offering. The Richmond ...

In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less underwriting discounts ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Celebrating his company’s upsized initial public offering (IPO), Septerna CEO Jeffrey Finer rang the opening bell on the Nasdaq stock exchange on Friday morning in New York, in the latest sign ...

with a 40% probability of success, via peak penetration of 15% as an add-on therapy in the incretin-treated market. BioAge (BIOA) held an upsized initial public offering on Sept. 26, raising $198M.

RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million init ... Subscribe now to see this Premium News article from Alliance News ...

In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less underwriting discounts ...